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Most physiological and biotechnological processes rely on molec-
ular recognition between chiral (handed) molecules. Manmade
homogeneous catalysts and enzymes offer complementary means
for producing enantiopure (single-handed) compounds. As the
subtle details that govern chiral discrimination are difficult to
predict, improving the performance of such catalysts often relies
on trial-and-error procedures. Homogeneous catalysts are opti-
mized by chemical modification of the chiral environment around
the metal center. Enzymes can be improved by modification of
gene encoding the protein. Incorporation of a biotinylated orga-
nometallic catalyst into a host protein (avidin or streptavidin)
affords versatile artificial metalloenzymes for the reduction of
ketones by transfer hydrogenation. The boric acidformate mixture
was identified as a hydrogen source compatible with these artifi-
cial metalloenzymes. A combined chemo-genetic procedure allows
us to optimize the activity and selectivity of these hybrid catalysts:
up to 94% (R) enantiomeric excess for the reduction of p-methy-
lacetophenone. These artificial metalloenzymes display features
reminiscent of both homogeneous catalysts and enzymes.
second coordination sphere  asymmetric catalysis  chemzymes
The asymmetric reduction of CAO and CAN bonds is one ofthe most fundamental transformations in organic chemistry
(1–3). Although enzymatic and organometallic catalysis have
evolved along very different paths, both methodologies can
achieve high levels of enantioselection for this transformation.
Oxidoreductases such as alcohol dehydrogenases can perform
this task very efficiently and selectively (4–7). To achieve this,
however, these enzymes rely on precious cofactors NAD(P)H,
which need to be regenerated (8). Alternatively, whole cells can
be used. These contain multiple dehydrogenases, all of the
necessary cofactors, and the metabolic pathways for their re-
generation (5).
Asymmetric transfer hydrogenation (Meerwein-Ponndorf-
Verley reduction) based on d6 piano-stool complexes has proven
to be versatile for the asymmetric reduction of ketones and
imines (2, 9, 10). Regeneration of the organometallic hydride is
achieved by a -H abstraction between the catalyst precursor and
a sacrificial hydrogen donor (isopropanol or formate). These
catalysts nicely complement other organometallic systems that
rely on dihydrogen (3).
It is interesting to note that theoretical studies suggest that the
transfer hydrogenation catalyzed by d6 piano-stool complexes
proceeds without coordination of the substrate to the metal, as
illustrated in transition-state structure 1 (11–14) (Fig. 1). The
chiral recognition pattern for this organometallic transformation
is thus reminiscent of enzymatic catalysis. Indeed, the second
coordination sphere provided by a protein is optimized to steer
the enantiodiscrimination step without necessarily requiring
covalent (or dative) binding of the substrate to the enzyme.
In recent years, chemo-enzymatic catalysis has attracted increas-
ing attention. In such systems, an enzyme is combined with an
organometallic catalyst to afford versatile hybrid catalysts. In this
context, the propensity of d6 piano-stool metal complexes to
undergo -H abstraction in the presence of an alcohol or formate
has been exploited in combination with enzymes to yield chemo-
enzymatic systems (15–20). For example, combining a lipase (which
acylates exclusively one enantiomer of a secondary alcohol) with a
[5-(Ph4C5O)Ru(CO)2] moiety (which racemizes the alcohol by
-H abstraction followed by an insertion) allows the dynamic
kinetic resolution of secondary alcohols by acylation (15, 20).
Another elegant hybrid catalyst example relies on the -H abstrac-
tion propensity of [5-(Me5C5)Rh(bpy)(H2O)]2 toward formate to
regenerate the precious flavin cofactor of styrene monooxygenase
and to produce (S)-styrene oxide from styrene in nearly enantio-
pure form [enantiomeric excess (ee) 99%] (19).
These two examples of chemo-enzymatic catalysis demon-
strate that the typical -H abstraction–insertion reactivity of d6
piano-stool complexes is maintained despite the abundance of
donor functionalities present on the surface of an enzyme. With
the aim of creating artificial transfer hydrogenases for the
enantioselective reduction of ketones, we set out to anchor a d6
piano-stool complex within a host protein. We reasoned that, as
the substrate does not bind to the metal center during transfer
hydrogenation (see 1, Fig. 1), a well defined second coordination
sphere provided by the host protein around a piano-stool
complex offers an attractive mean for optimizing the selectivity
of transfer hydrogenation catalysts. The general concept is
outlined in Scheme 1.
With the aim of creating artificial metalloenzymes, both
covalent and noncovalent anchoring strategies of organometallic
species with a well defined first coordination sphere are currently
being pursued by various groups (21–25). Inspired by the work
of Wilson and Whitesides (26), we have recently exploited
biotin-avidin technology to ensure the localization of a [Rh(di-
phosphine)]-moiety in a chiral environment provided by the
(strept)avidin, (strept)avidin refers to either avidin or strepta-
Abbreviation: ee, enantiomeric excess.
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vidin (26–30). Herein, we present our efforts to extend this
methodology to the transfer hydrogenation of ketones by using
biotinylated d6 piano-stool complexes in conjunction with
(strept)avidin.
Methods
(Strept)avidin was produced, purified, and quantified according to
ref. 28. All experiments were carried out by using standard Schlenk
techniques, with thoroughly degassed solutions (nitrogen-flushed).
Preparation of [6-(arene)Ru(Biot–q–L)Cl]. The ruthenium dimer
[6-(arene)RuCl2]2 (arene  benzene, p-cymene; q  ortho,
meta, para) (38.8 mol, 1.00 eq.), the biotinylated ligand Biot–
q–LH (37.8 mg, 85.5 mol, 2.20 eq.), and NEt3 (12.5 l, 90 mol,
2.25 eq.) were dissolved in isopropanol (1.5 ml) and heated at
80°C for 2 h. The solvent was removed in vacuo to afford a
red-brown powder that was stored under nitrogen until use. For
catalysis purposes, the crude catalyst precursor [6-(arene)Ru-
(Biot–q–L)Cl] was dissolved in degassed dimethylformamide to
a final stock solution concentration of [Ru]  0.0395 M. This
stock solution can be stored for several days without any
noticeable loss in activity or selectivity.
Boric AcidFormate Mixed Buffer. Boric acid (1.05 g, 17 mmol) and
sodium formate (1.36 g, 20 mmol) were dissolved in water (20 ml).
The pH was adjusted to 6.25 with NaOH pellets. The final stock-
solution concentration was B(OH)3  0.85 M, HCO2Na  1 M.
Catalysis Experiments. (Strept)avidin was dissolved in water [100
M tetrameric concentration (31)] and thoroughly degassed.
The host protein (450 l, 0.045 mol, 1.4 eq. active sites vs.
ruthenium) was mixed in a test tube (7 ml capacity) with the
precursor complex [6-(arene)Ru(Biot–q–L)Cl] (3.3 l of the
dimethylformamide stock solution, 0.13 mol ruthenium) and
stirred at room temperature for 10 min. The boric acidformate
mixed buffer (550 l of the stock solution, 42 eq. formate vs.
substrate 2 a-c), and, if required, the Mops buffer (200 l of 1
M stock solution in water, pH 6.25, as well as an additional 50
l of the boric acidformate stock solution) were added and
stirred for 5 min. Finally, substrate 2 a-c (13 l of a 1 M stock
solution in dimethylformamide, 13 mol, 100 eq. vs. ruthenium)
was added. The test tube was placed in a magnetically stirred 24
multireactor (Greenhouse Parallel Synthesizer from Radleys,
Brinkmann), purged four times with nitrogen, and heated at
45–55°C for 40–64 h. After completion, the reaction mixture was
extracted four times with Et2O (4  1 ml) and dried over
Na2SO4. Subsequent continuous extraction of the resulting
aqueous phase reveals no trace of substrate 2 a-c or product 3 a-c.
The organic solution was filtered through a short silica plug that
was thoroughly washed with Et2O, concentrated, and subjected
to HPLC analysis using a Chiralcel OB-H column (Daicel
Chemical Industries, Tokyo) with hexaneisopropanol at 97:3 at
0.7 mlmin. Identical results were obtained for the best ees with
samples that were not subjected to filtration through a silica plug.
For 1-phenylethanol 3a, tS  18.18 min and tR  26.45 min
(UV detection at 215 nm, absolute configuration determined
with a commercial enantiopure sample).
For 1-(p-bromophenyl)ethanol 3b, tS  17.33 min and tR 
19.44 min [UV detection at 225 nm, absolute configuration (32)].
For 1-(p-methyphenyl)ethanol 3c, tS  19.14 min and tR 
22.16 min [UV detection at 215 nm, absolute configuration (33)].
Scheme 1. Artificial metalloenzymes for enantioselective transfer hydroge-
nation reactions. The host protein displays high affinity for the anchor (tri-
angle); introduction of a spacer (rectangle) and variation of the d6 piano-stool
moiety allows us to chemically optimize the enantioselectivity. Site-directed
mutagenesis allows for a genetic optimization of the host protein.
Scheme 2. Biotinylated ligand synthesis and in situ catalyst precursor generation. CDMT, 2-chloro-4,6-dimethoxy-1,3,5-triazine; TFA, trifluoracetic acid.
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Results and Discussion
The most successful ligands for enantioselective transfer hydro-
genation with d6 piano-stool complexes in organic solvents are
often amino alcohols, amino-sulfonamides, and diimine ligands
(2, 9, 10, 34). In aqueous solvents, themost promising systems are
based on water-soluble or polymer-supported amino-sulfon-
amide scaffolds derived from Noyori’s system (35–40). In the
same spirit, we synthesized a series of achiral aminosulfonamide
ligands Biot–q–LH (Scheme 2) and set out to test their potential
in combination with two [6-(arene)Ru]2 moieties by using
(strept)avidin as host proteins.
The catalyst precursors [6-(arene)Ru(Biot–q–L)Cl] were pre-
pared in situwith isopropanol and triethylamine. Such complexes
are chiral at ruthenium. The absence of a CD signal in their
absorption band strongly suggests that these complexes are
formed as a 1:1 mixture of epimers at ruthenium. As a conse-
quence, in the absence of (strept)avidin, all catalysts (1 mol% vs.
acetophenone 2a) produce quantitatively (rac)-phenylethanol 3a
at 45°C within 40 h of using either isopropanol, the
triethylamineformic acid azeotropic mixture, or 1.5 M sodium
formate as the hydrogen source. These experiments demonstrate
that the catalyst precursors are indeed active, but unselective,
transfer hydrogenation catalysts.
Under similar reaction conditions but in the presence of
(strept)avidin {1 mol% [6-(cymene)Ru(Biot–p–L)Cl], 0.34
mol% tetrameric streptavidin, Scheme 3}, we observed the
slow appearance of a white precipitate. Nondenaturing gel
electrophoresis (41, 42) of the turbid mixture reveals the
presence of monomeric (strept)avidin, suggesting that these
reducing agents denature (strept)avidin. Decreasing the for-
mate concentration to 0.5 M (42 eq. vs. acetophenone) allows
us to totally suppress the denaturation of the host protein, thus
ensuring that the chiral environment provided by the host
protein remains unaltered throughout catalysis [conversion
51%, ee 28% (R), Table 1, entry 1].
With the aim of stabilizing the pH during catalysis (43),
various acids were screened in combination with 0.5 M sodium
formate. These experiments revealed that the mixed buffer
HCO2NaB(OH)3 (pHinitial 6.25, pHfinal 7.5 with boric acid,
pHfinal 8.5 without boric acid) has a beneficial effect on the ee
[conversion 55%, ee 57% (R), Table 1, entry 2].
Having identified a reducing source compatible with the
artificial metalloenzyme, we tested various biotinylated catalyst
precursors [6-(arene)Ru(Biot–q–L)Cl] in conjunction with WT
(strept)avidin (WT-Avi and WT-Sav respectively; Table 1).
These experiments reveal the following trends:
(i) The para-anchored ligand Biot–p–L outperforms both the
ortho- and the meta-diastereomers Biot–o–L and Biot–m–L in
terms of activity and selectivity (Table 1, compare entries 2, 4,
and 5).
(ii) Streptavidin is a better host protein than avidin (Table 1,
compare entries 2 and 3 and 6 and 7).
(iii) With streptavidin as host protein, substitution of the
6-(p-cymene)- by an 6-benzene cap on the biotinylated piano-
stool complex produces the opposite enantiomer of phenyletha-
nol {57% (R), 55% conversion for [6-(p-cymene)Ru(Biot–p–
L)Cl]streptavidin and 56% ee (S), 29% conversion for [6-
(benzene)Ru(Biot–p–L)Cl]streptavidin, respectively; Table 1,
entries 2 and 6}.
Having identified the best biotinylated ligand–6-arene com-
binations, we proceeded to genetically optimize the performance
of the artificial metalloenzyme by introducing point mutations
within the host protein. For this purpose, a recombinant avidin
with a lowered isoelectric point (r-GAvi, pI  5.4) (44) and five
streptavidin mutants (S112G Sav, K80G Sav, V47G Sav, P64G
Sav, and the double mutant P64G S112G Sav) (28) were
screened. For the reduction of acetophenone using the boric
acidformate mixed buffer, some additional general trends
emerge (Table 2):
(i) The host protein with the mutation closest to the catalytic
site (S112G Sav) affords the highest conversions but the lowest
selectivity {28% ee (R), 90% conversion using [6-(p-
cymene)Ru(Biot–p–L)Cl]S112G Sav; 8% ee (S), 42% conver-
sion using [6-(benzene)Ru(Biot–p–L)Cl]S112G Sav; Table 2,
entries 2 and 7}.
(ii) The host protein with the most remote site of mutation
(P64G Sav) has the greatest influence on the enantioselectivity
Scheme 3. Transfer hydrogenation of acetophenone derivatives 2 a-c cat-
alyzed by artificial metalloenzymes.
Table 1. Selected results for the chemical optimization of the
performance of [6-(arene)Ru(Biot–q–L)Cl](strept)avidin as an
artificial metalloenzyme for the transfer hydrogenation of
acetophenone 2a
Entry Ligand 6-arene Protein Conversion, % ee, %
1* Biot–p–L p-cymene WT-Sav 51 28 (R)
2† Biot–p–L p-cymene WT-Sav 55 57 (R)
3† Biot–p–L p-cymene WT-Avi 24 22 (R)
4† Biot–m–L p-cymene WT-Sav 20 6 (S)
5† Biot–o–L p-cymene WT-Sav 18 3 (S)
6† Biot–p–L Benzene WT-Sav 29 56 (S)
7† Biot–p–L Benzene WT-Avi 17 17 (R)
All catalytic runs were carried out at 45°C for 40 h at pHinitial  6.25, using
a Ruacetophenone 2aformate ratio of 1:100:4,200. Conversions and enan-
tioselectivities were determined by HPLC on Chiralcel OB-H.
*Nonbuffered 0.5 M formate solution.
†Mixed buffer HCO2Na (0.5 M)  B(OH)3 (0.47 M).
Table 2. Selected results for the genetic optimization of the
performance of [6-(arene)Ru(Biot–p–L)Cl](strept)avidin as
an artificial metalloenzyme for the transfer hydrogenation
of acetophenone 2a by using formateboric acid as a
reducing agent
Entry Ligand 6-arene Protein Conversion, % ee, %
1 Biot–p–L p-cymene r-GAvi 40 22 (R)
2 Biot–p–L p-cymene S112G Sav 90 28 (R)
3 Biot–p–L p-cymene V47G Sav 42 68 (R)
4 Biot–p–L p-cymene K80G Sav 54 65 (R)
5 Biot–p–L p-cymene P64G Sav 54 72 (R)
6 Biot–p–L p-cymene P64G S112G Sav 95 58 (R)
7 Biot–p–L Benzene S112G Sav 42 8 (S)
8 Biot–p–L Benzene V47G Sav 8 56 (S)
9 Biot–p–L Benzene K80G Sav 31 51 (S)
10 Biot–p–L Benzene P64G Sav 30 58 (S)
All catalytic runs were carried out at 45°C for 40 h at pHinitial  6.25, using
a Ruacetophenone 2aformate ratio of 1:100:4,200, by using the mixed
buffer HCO2Na (0.5 M)B(OH)3 (0.47 M) as a formate source. Conversions and
enantioselectivities were determined by HPLC on Chiralcel OB-H.
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{72% ee (R), 54% conversion for [6-(p-cymene)Ru(Biot–p–
L)Cl]P64G Sav; 58% ee (S), 30% conversion with [6-
(benzene)Ru(Biot–p–L)Cl]P64G Sav; Table 2, entries 5 and 10}.
(iii) The double mutant P64G S112G Sav (Table 2, entry 6)
combines the features of both single mutants P64G (increased
selectivity vs. WT Sav) and increased activity S112G (increased
activity vs. WT Sav).
With the aim of further stabilizing the pH 6.25, various
buffers were screened. Addition of 0.15 M Mops [3-(N-
morpholino)propanesulfonic acid sodium salt, pHfinal 7.0] to
the formateboric acid mixture has a beneficial effect on the
enantioselectivity, at the cost of a slightly lower conversion,
however (compare Table 3, entries 1 and 2 with Table 1, entries
2 and 6). To overcome this drawback, the temperature was raised
from 45°C to 55°C, and the reaction time was extended to 64 h
(Table 3, entry 3). In the presence of Mops at 55°C, [6-(p-
cymene)Ru(Biot–p–L)Cl]P64G Sav affords (R)-phenylethanol
in 85% ee (R) in 90% conversion (Table 3, entry 4, compare with
Table 2, entry 5).
Next, p-bromoacetophenone 2b and p-methylacetophenone 2c
were tested in conjunction with [6-(p-cymene)Ru(Biot–p–
L)Cl]P64G Sav and [6-(benzene)Ru(Biot–p–L)Cl]P64G
Sav. Again with these substrates, the p-cymene-capped and the
benzene-capped catalysts afford the opposite enantiomers
within the same host protein (Table 3, entries 4–6 and 10–11).
For example, the reduction of p-methylacetophenone 2c affords
p-tolylethanol in 94% ee (R) with 92% conversion and in 44%
(S) with 44% conversion by using [6-(p-cymene)Ru(Biot–p–
L)Cl]P64G Sav and [6-(benzene)Ru(Biot–p–L)Cl]P64G
Sav, respectively (Table 3, entries 6 and 11).
It is interesting to note that increasing the temperature has a
beneficial effect on both the conversion and enantioselectivity
for the p-cymene-capped catalyst; in contrast, it has a detrimen-
tal effect on enantioselectivity for the benzene-capped catalyst
(Table 3, compare entries 10 and 11).
At 55°C, the double mutant [6-(p-cymene)Ru(Biot–p–
L)Cl]P64G S112G Sav produces quantitatively all three phe-
nylethanol derivatives (2 a-c) within 40 h with selectivities
intermediate between the WT Sav and P64G Sav (Table 3,
entries 7–9).
Outlook
The study of artificial transfer hydrogenases based on biotin-
avidin technology reveals several noteworthy features:
(i) Having identified a source of hydrogen compatible with
streptavidin, biotinylated three-legged piano-stool complexes
are versatile enantioselective transfer hydrogenation catalysts.
(ii) As the first coordination sphere around ruthenium is
achiral, enantioselection is determined by second coordination
sphere interactions. In this context, the choice of capping arene
(either 6-p-cymene or 6-benzene) plays a critical role in
determining which enantiomer of the product is produced
preferentially. To rationalize this observation, two complemen-
tary enantioselection mechanisms can be envisaged. On one
hand, protein–substrate interactions may favor the preferential
approach of one prochiral face of the substrate. On the other
hand, streptavidin–[6-(arene)Ru(Biot–q–L)Cl] contacts may
enforce one configuration at ruthenium [(RRu) or (SRu)] (45).
This configuration, in turn, could determine which prochiral face
of the substrate undergoes reduction. These two possibilities are
summarized in Scheme 4.
(iii) Both chemical and genetic methodologies [i.e., chemoge-
netic (46)] can be efficiently combined to optimize the activity
and selectivity of the artificial metalloenzymes [up to 94% ee (R)
with 92% conversion with 1 mol% catalyst loading]. This ap-
proach thus adds another dimension to catalyst discovery and
optimization.
In the spirit of enzymatic catalysis, providing a well defined
second coordination sphere for a transition state that does not
involve coordination of the substrate to the metal (see 1, Fig. 1)
is a promising approach. Additional efforts in this area should be
centered on the microscopic reverse reaction: the kinetic reso-
lution of secondary alcohols by Oppenauer oxidation.
We thank Belovo Egg Science and Technology (Bastogne, Belgium) for
a generous gift of avidin and C. R. Cantor (Boston University, Boston)
Scheme 4. Postulated second coordination sphere interactions between
streptavidin and either [6-(arene)Ru(Biot–p–L)Cl] or the substrate. Depend-
ing on the6-arene cap, SRustreptavidin orRRustreptavidin may be favored.
Table 3. Selected results for the optimization of the performance of [6-(arene)Ru(Biot–p–L)Cl](strept)avidin as an artificial
metalloenzyme for the transfer hydrogenation of acetophenone derivatives 2a-c by using formateboric acid as a reducing agent in
0.15 M Mops buffer
Entry Ligand 6-arene Protein Substrate Temperature, °C Time, h Conversion, % ee, %
1 Biot–p–L p-cymene Sav 2a 45 40 40 66 (R)
2 Biot–p–L Benzene Sav 2a 45 40 30 63 (S)
3 Biot–p–L p-cymene Sav 2a 55 64 82 68 (R)
4 Biot–p–L p-cymene P64G Sav 2a 55 64 90 85 (R)
5 Biot–p–L p-cymene P64G Sav 2b 55 64 97 89 (R)
6 Biot–p–L p-cymene P64G Sav 2c 55 64 92 94 (R)
7 Biot–p–L p-cymene P64G S112 G Sav 2a 55 40 Quantitative 67 (R)
8 Biot–p–L p-cymene P64G S112 G Sav 2b 55 40 Quantitative 88 (R)
9 Biot–p–L p-cymene P64G S112 G Sav 2c 55 40 Quantitative 90 (R)
10 Biot–p–L Benzene P64G Sav 2c 45 64 34 57 (S)
11 Biot–p–L Benzene P64G Sav 2c 55 64 44 44 (S)
All catalytic runs were carried out at pHinitial  6.25 by using the mixed buffer HCO2Na (0.5 M)  B(OH)3 (0.47 M) combined with Mops (0.15 M) with a
Rusubstrate 2 a-cformate ratio of 1:100:4,500. Conversions and enantioselectivity were determined by HPLC on Chiralcel OB-H.
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